Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil

Frontiers in Microbiology

Volumn 6, Issue APR, 2015, Pages

  Coelho, Tatiane ^a,b   Machado, Diana ^c   Couto, Isabel ^c   Maschmann, Raquel ^a,b   Ramos, Daniela ^d   Groll, Andrea von ^d   Rossetti, Maria L ^a,b   Silva, Pedro A ^d   Viveiros, Miguel ^c  

^a Fundacao Estadual de Producao e Pesquisa em Saude   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^d FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

Author keywords

Checkerboard; Drug resistance; Fluorometry; Fractional inhibitory concentration; TEMA; Tuberculosis

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CHLORPROMAZINE; EFFLUX INHIBITOR; ETHIDIUM BROMIDE; ISONIAZID; MESSENGER RNA; OFLOXACIN; RIFAMPICIN; TETRAZOLIUM; THIORIDAZINE; TOXIC SUBSTANCE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BIOASSAY; BRAZIL; CONTROLLED STUDY; DRUG POTENTIATION; EFFUSION; FLUORESCENCE; FLUOROMETRY; FRACTIONAL INHIBITORY CONCENTRATION; GENE EXPRESSION; GENOTYPE PHENOTYPE CORRELATION; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; MODULATION FACTOR; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84930941347     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.00330     Document Type: Article

References (40)

1. Böttger, E. C. (2011). The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin. Microbiol. Infect. 17, 1128-1134. doi: 10.1111/j.1469-0691.2011.03551.x.
2. Brennan, P. J., and Nikaido, H. (1995). The envelope of mycobacteria. Annu. Rev. Biochem. 64, 29-63. doi: 10.1146/annurev.bi.64.070195.000333.
3. Bustin, S. A. (2000). Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25, 169-193. doi: 10.1677/jme.0.0250169.
4. Cambau, E., Viveiros, M., Machado, D., Raskine, L., Ritter, C., Tortoli, E., et al. (2015). Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J. Antimicrob. Chemother. 70, 686-696. doi: 10.1093/jac/dku438.
5. Caviedes, L., Delgado, J., and Gilman, R. (2002). Tetrazolium microplate assay as a rapid and inexpensive colorimetric method for determination of antibiotic susceptibility of Mycobacterium tuberculosis. J. Clin. Microbiol. 40, 1873-1874. doi: 10.1128/JCM.40.5.1873-1874.2002.
6. Costa, S. S., Falcão, C., Viveiros, M., Machado, D., Martins, M., Melo-Cristino, J., et al. (2011). Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol. 11:241. doi: 10.1186/1471-2180-11-241.
7. De Rossi, E., Ainsa, J. A., and Riccardi, G. (2006). Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol. Rev. 30, 36-52. doi: 10.1111/j.1574-6976.2005.00002.x.
8. Dutta, N. K., and Karakousis, P. C. (2014). Thioridazine for treatment of tuberculosis: promises and pitfalls. Tuberculosis 94, 708-711. doi: 10.1016/j.tube.2014.09.001.
9. Eliopoulos, G. M., and Moellering, R. C. Jr (1996). "Antimicrobial combinations," in Antibiotics in Laboratory Medicine, 4th Edn, ed V. Lorian (Baltimore, MD: Williams and Wilkins), 330-396.
10. Gomez-Flores, R., Gupta, S., Tamez-Guerra, R., and Mehta, R. T. (1995). Determination of MICs for Mycobacterium avium-M. intracellulare complex in liquid medium by a colorimetric method. J. Clin. Microbiol. 33, 1842-1846.
11. Green, K. D., and Garneau-Tsodikova, S. (2013). Resistance in tuberculosis: what do we know and where can we go? Front. Microbiol. 23, 4:208. doi: 10.3389/fmicb.2013.00208.
12. Gröblacher, B., Kunert, O., and Bucar, F. (2012). Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis. Bioorg. Med. Chem. 20, 2701-2706. doi: 10.1016/j.bmc.2012.02.039.
13. Gupta, S., Tyagi, S., Almeida, D. V., Maiga, M. C., Ammerman, N. C., and Bishai, W. R. (2013). Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am. J. Respir. Crit. Care Med. 188, 600-607. doi: 10.1164/rccm.201304-0650OC.
14. Kigondu, E. M., Warner, D. F., Njoroge, M., and Chibale, K. (2014). Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites. Med. Chem. Commun. 5, 502-506. doi: 10.1039/c3md00387f.
15. Li, X. Z., and Nikaido, H. (2009). Efflux-mediated drug resistance in bacteria: an update. Drugs 69, 1555-1623. doi: 10.2165/11317030-000000000-00000.
16. Louw, G. E., Warren, R. M., Gey van Pittius, N. C., Leon, R., Jimenez, A., Hernandez-Pando, R., et al. (2011). Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184, 269-276. doi: 10.1164/rccm.201011-1924OC.
17. Machado, D. (2014). The Dynamics of Drug Resistance in Mycobacterium tuberculosis: Exploring the Biological Basis of Multi-and Extensively Drug Resistant Tuberculosis (MDR/XDRTB) as a Route for Alternative Therapeutic Strategies. Ph.D thesis, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa.
18. Machado, D., Couto, I., Perdigão, J., Rodrigues, L., Portugal, I., Baptista, P., et al. (2012). Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS ONE 7:e34538. doi: 10.1371/journal.pone.0034538.
19. Machado, L., Spengler, G., Evaristo, M., Handzlik, J., Molnár, J., Viveiros, M., et al. (2011). Biological activity of twenty-three hydantoin derivatives on intrinsic efflux pump system of Salmonella enterica serovar Enteritidis NCTC 13349. In Vivo 25, 769-772.
20. Mahamoud, A., Chevalier, J., Alibert-Franco, S., Kern, W. V., and Pagès, J. M. (2007). Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Chemother. 59, 1223-1229. doi: 10.1093/jac/dkl493.
21. Marquez, B. (2005). Bacterial efflux systems and efflux pumps inhibitors. Biochimie 87, 1137-1147. doi: 10.1016/j.biochi.2005.04.012.
22. Maschmann, R. A., Ribeiro, A. W., Machado, T. R. M., Spies, F. S., Zaha, A., Nunes, L. S., et al. (2013). Performance of the GenoType MTBDRplus assay directly on sputum specimens from Brazilian patients with tuberculosis treatment failure or relapse. J. Clin. Microbiol. 51, 1606-1608. doi: 10.1128/JCM.00364-13.
23. Moody, J. A. (1992). Synergism Testing: Broth Microdilution Checkerboard and Broth Macrodilution Methods. Washington, DC: American Society for Microbiology.
24. Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52, 1. doi: 10.1093/jac/dkg301.
25. Piddock, L. (2006). Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19, 382-402. doi: 10.1128/CMR.19.2.382-402.2006.
26. Pillai, S., Moellering, R., and Eliopoulos, G. (2005). "Antimicrobial combinations," in Antibiotics in Laboratory Medicine, 5th Edn, ed V. Lorian (Baltimore, MD: Williams and Wilkins), 365-440.
27. Rodrigues, L., Machado, D., Couto, I., Amaral, L., and Viveiros, M. (2012). Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect. Genet. Evol. 12, 695-700. doi: 10.1016/j.meegid.2011.08.009.
28. Rodrigues, L., Ramos, J., Couto, I., Amaral, L., and Viveiros, M. (2011). Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. BMC Microbiol. 11:35. doi: 10.1186/1471-2180-11-35.
29. Rodrigues, L., Sampaio, D., Couto, I., Machado, D., Kern, W. V., Amaral, L., et al. (2009). The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. Int. J. Antimicrob. Agents. 34, 529-533. doi: 10.1016/j.ijantimicag.2009.07.010.
30. Schmalstieg, A. M., Srivastava, S., Belkaya, S., Deshpande, D., Meek, C., Leff, R., et al. (2012). The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob. Agents Chemother. 56, 4806-4815. doi: 10.1128/AAC.05546-11.
31. Silva, P. E. A., and Palomino, J. C. (2011). Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 66, 1417-1430. doi: 10.1093/jac/dkr173.
32. Somoskovi, A., Dormandy, J., Mitsani, D., Rivenburg, J., and Salfinger, M. (2006). Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J. Clin. Microbiol. 44, 4459-4463. doi: 10.1128/JCM.01506-06.
33. Viveiros, M., Martins, M., Rodrigues, L., Machado, D., Couto, I., Ainsa, J., et al. (2012). Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev. Anti Infect. Ther. 10, 983-998. doi: 10.1586/eri.12.89.
34. Viveiros, M., Rodrigues, L., Martins, M., Couto, I., Spengler, G., Martins, A., et al. (2010). "Evaluation of efflux activity of bacteria by a semi-automated fluorometric system," in Antibiotic Resistance Methods and Protocols, Methods in Molecular Medicine, 2nd Edn, Vol. 642, ed S. H. Gillespie (New York, NY: Humana Press), 159-172.
35. Wei, C.-J., Lei, B., Musser, J. M., and Tu, S.-C. (2003). Isoniazid activation defects in recombinant Mycobacterium tuberculosis catalase-peroxidase (KatG) mutants evident in InhA inhibitor production. Antimicrob. Agents Chemother. 47, 670-675. doi: 10.1128/AAC.47.2.670-675.2003.
36. Williams, D. L., Spring, L., Collins, L., Miller, L. P., Heifets, L. B., Gangadharam, P. R., et al. (1998). Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42, 1853-1857.
37. World Health Organization. (2008). Anti-Tuberculosis Drug Resistance in the World. Fourth Global Report. WHO/HTM/TB/2008.394, Geneva.
38. World Health Organization. (2013). Global Tuberculosis Report. WHO/HTM/TB/2013.11, Geneva.
39. World Health Organization. (2014). Global Tuberculosis Report 2014. WHO/HTM/TB/2014.08, Geneva.
40. Yin, J. L., Shackel, N. A., Zerry, A., McGuinness, P. H., Richards, C., van der Putten, K., et al. (2001). Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol. Cell Biol. 79, 213-221. doi: 10.1046/j.1440-1711.2001.01002.x.